Publication | Open Access
Phase-1 Clinical Trial Results of High-Specific-Activity Carrier-Free <sup>123</sup>I-Iobenguane
21
Citations
14
References
2014
Year
Human normal-organ kinetics, radiation dosimetry, clinical safety, and imaging efficacy provide compelling evidence for the use of high-specific-activity (123)I-iobenguane.
| Year | Citations | |
|---|---|---|
Page 1
Page 1